% Expired Patents = 20.0

CIPO Patents = 2

EPO Patents = 2

Forward Citations = 17

Loading Chart...

9 inventors (with patents filed for the assignee):

William Guy Love (5 out of 11 patents)

William Rhys-Williams (5 out of 5 patents)

Derek Brundish (3 out of 3 patents)

4. Benoit Pugin (2 out of 20 patents)

5. Xiang Feng (1 out of 2 patents)

6. Andrew W Lloyd (1 out of 2 patents)

7. Matteo Santin (1 out of 5 patents)

8. Xiang Dong Feng (1 out of 1 patent)

9. Stephen P Denyer (1 out of 1 patent)

10. William Love (0 patent)

11. William G Love (0 patent)

12. William G Love (0 patent)

5 patents: Sort by Forward Citations

1. 9326511 - Methods of inhibiting microbial biofilms (2016-05-03),

2. 8084602 - Porphyrin derivatives and their use in photodynamic therapy (2011-12-27),

3. 7977474 - Uses of porphyrin compounds (2011-07-12),

4. 7244841 - Porphyrin derivatives and their use in photodynamic therapy (2007-07-17),

5. 6863693 - Phospholipid-coated implants (2005-03-08),

Destiny Pharma is a clinical-stage biotechnology company focused on the development of novel anti-infectives to prevent infections. Their lead product XF-73 is being developed for the prevention of post-surgical infections, resistant bacterial infections and hospital-acquired infections. They are also working on other pipeline products that target drug-resistant infections.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

5 Patents

#5 in Brighton

#3,210 in United Kingdom

Brighton, United Kingdom

Destiny Pharma Limited

Forward Citations = 17

9 inventors:

William Guy Love (5 out of 11 patents)

William Rhys-Williams (5 out of 5 patents)

Derek Brundish (3 out of 3 patents)

4. Benoit Pugin (2 out of 20 patents)

5. Xiang Feng (1 out of 2 patents)

Please report any incorrect information to [email protected]

2 patents (CIPO):

Please report any incorrect information to [email protected]

2 patents (EPO):

Please report any incorrect information to [email protected]